Transplant and Cell TherapyNCT06431347
Prospective Observational Cohort Study of Transplant and Cell Therapy Candidates and Recipients to Assess Social Determinants of Health
An observational study of Transplant and Cell Therapy, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To learn more about social and financial factors that may influence outcomes of TCT treatment at MD Anderson. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Transplant and Cell Therapy
- What is being tested?
- Social Determinants of Health Questionnaire
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 2,000 participants
- Where
- 1 siteUnited States
- Study dates
- 17 Jun 2024to 1 Jun 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: MD Anderson Cancer Center
Who may be able to join
- ≥ 18 years of age.
- Received financial clearance for TCT.
- Qualitative study - patients
- Patient ≥ 18 years of age who is currently cared for at MD Anderson as a TCT candidate/ recipient,
- The patient reports social and/or financial challenges impacting care delivery.
- The patient is willing to participate in a semi-structured interview.
Show all 17Show fewer
- Qualitative study - caregivers
- Caregiver(s) of a patient ≥ 18 years of age who is currently cared for at MD Anderson as a TCT candidate/ recipient.
- The patient reports social and/or financial challenges impacting care delivery.
- The patient has referred the caregiver(s) to participate and provided us with permission to contact their caregiver(s).
- The caregiver(s) is (are) willing to participate in a semi-structured interview.
- Exclusion Criteria Patients - Quantitative study 1) Did not receive financial clearance for TCT
- Patients - Qualitative study
- 1) Not impacted by social or financial challenges.
- Caregivers (qualitative study)
- Did not care for a patient impacted by social or financial challenges
- Were not referred to participate in the study by patient they cared for.
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
MD Anderson Cancer Center
Houston, Texas, 77030
Warren Fingrut, MD, 832-387-8363, wbfingrut@mdanderson.org
Warren Fingrut, MD
About this study
To learn more about social and financial factors that may influence outcomes of TCT treatment at MD Anderson.
Read the detailed description
Primary Objective:
To determine the relationship between participant social determinants of health (SDOH) and outcomes following transplantation and cellular therapy at MDACC.
- Conditions
- Transplant and Cell Therapy
- Being tested
- Social Determinants of Health Questionnaire
- Keywords
- Social Determinants of Health
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Social Determinants of Health QuestionnaireBehavioural
Participants will also complete a questionnaire about financial barriers to care within the past year, including income bracket and difficulty affording cost-of-living or medical expenses.
| Study group | Role | What they receive |
|---|---|---|
| Transplant and Cell Therapy Candidates and Recipients | Participants that agree to take part in this study, the study staff will first verify your demographic information (such as age, sex, race, and so on). Participants will then be asked about social barriers to care, including but not limited to:
* primary language and confidence speaking English
* education level
* employment history
* health literacy
* legal history
* caregiver status and literacy Receives: Behavioral: Social Determinants of Health Questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Social Determinants of Health Questionnaire
Measured: At 6, 12, 18, and 24 months post Transplant and Cell Therapy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 May 2024
- Study start17 Jun 2024
- Primary completion1 Jun 2027 (estimated)
- Study completion1 Jun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Transplant and Cell TherapyStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Warren Fingrut, MD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06431347
- Sponsor's protocol ID
- 2024-0038
- Other IDs
- NCI-2024-04536
- Status last verified
- Sep 2026
- First submitted
- 22 May 2024
- Last updated
- 18 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Observational Cohort Study of Transplant and Cell Therapy Candidates and Recipients to Assess Social Determinants of Health
- ClinicalTrials.gov ID
- NCT06431347
- Acronym / sponsor ID
- 2024-0038
- Conditions
- Transplant and Cell Therapy
- Keywords
- Social Determinants of Health
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 17 Jun 2024 (actual)
- Primary completion
- 1 Jun 2027 (estimated)
- Study completion
- 1 Jun 2029 (estimated)
- First posted
- 28 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To learn more about social and financial factors that may influence outcomes of TCT treatment at MD Anderson.
Detailed description
Primary Objective:
To determine the relationship between participant social determinants of health (SDOH) and outcomes following transplantation and cellular therapy at MDACC.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Transplant and Cell Therapy Candidates and Recipients | – | Behavioral: Social Determinants of Health QuestionnaireParticipants that agree to take part in this study, the study staff will first verify your demographic information (such as age, sex, race, and so on). Participants will then be asked about social barriers to care, including but not limited to: * primary language and confidence speaking English * education level * employment history * health literacy * legal history * caregiver status and literacy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- MD Anderson Cancer Center
Key inclusion criteria (17 listed)
- ≥ 18 years of age.
- Received financial clearance for TCT.
- Qualitative study - patients
- Patient ≥ 18 years of age who is currently cared for at MD Anderson as a TCT candidate/ recipient,
- The patient reports social and/or financial challenges impacting care delivery.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Social Determinants of Health QuestionnaireParticipants will also complete a questionnaire about financial barriers to care within the past year, including income bracket and difficulty affording cost-of-living or medical expenses. | Behavioural | Transplant and Cell Therapy Candidates and Recipients |
Primary outcome
Social Determinants of Health Questionnaire
Time frame: At 6, 12, 18, and 24 months post Transplant and Cell Therapy
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2026.
- MD Anderson Cancer CenterLink provided by the sponsor.
Related trials for Transplant and Cell Therapy
Active, not recruitingPhase 1/2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Enrolling by invitationPhase 2
Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute Leukemia
Acute Leukemia, High Risk, Acute Leukemia Refractory
RecruitingPhase 1/2
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
RecruitingPhase 1/2
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Graft vs Host Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Warren Fingrut, MD principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Transplant and Cell Therapy, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Warren Fingrut, MD ((832) 387-8363, wbfingrut@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Social Determinants of Health Questionnaire (time frame: At 6, 12, 18, and 24 months post Transplant and Cell Therapy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.